<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808297</url>
  </required_header>
  <id_info>
    <org_study_id>3AL-CLN36</org_study_id>
    <nct_id>NCT04808297</nct_id>
  </id_info>
  <brief_title>Trehalose in Subjects With Neuronal Ceroid Lipofuscinoses</brief_title>
  <acronym>3AL-CLN36</acronym>
  <official_title>A Study in Subjects With Neuronal Ceroid Lipofuscinoses Taking Trehalose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Fondazione Stella Maris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Fondazione Stella Maris</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuronal Ceroid Lipofuscinoses (NCL) or Batten's disease are the most common juvenile&#xD;
      neurodegenerative disease, characterized by early blindness, movement disorders, cognitive&#xD;
      and behavioral impairment, epilepsy, and retinopathy.&#xD;
&#xD;
      This study aims to collect clinical and laboratory data of patients with NCL taking&#xD;
      Trehalose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline clinical status assessed using Annex VII of the Unified Batten Disease Rating Scale (UBDRS) (score 0-5 where 5 is the worst outcome) at 12 and 24 months</measure>
    <time_frame>month 0, month 12, month 24</time_frame>
    <description>Blood samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline using Annex VII of Unified Batten Disease Rating Scale (UBDRS) (score 0-5 where 5 is the worst outcome) at 12 and 24 months</measure>
    <time_frame>month 0, month 12, month 24</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Neuronal Ceroid-Lipofuscinoses</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects in regular clinical practice affected by CLN3 o CLN6 diagnose by genetic tests&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NCL genetic diagnosis (mutation in genes CLN3 or CLN6)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other concomitant neurodegenerative diseases.&#xD;
&#xD;
          -  Therapeutic and eating changes in the last four months prior to the study&#xD;
&#xD;
          -  Unstable clinical conditions (myoclonus worsening, instability in sleep, parenteral&#xD;
             nutrition)&#xD;
&#xD;
          -  Refusal to sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Filippo M Santorelli, MD PhD</last_name>
    <phone>+39050886231</phone>
    <email>filippo3364@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Fondazione Stella Maris</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucrecia A Mota, D.M.L</last_name>
      <phone>0039050992140</phone>
      <email>lucreciaantonia.mota@fsm.unipi.it</email>
    </contact>
    <investigator>
      <last_name>Ivana Ricca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Bajaj L, Lotfi P, Pal R, Ronza AD, Sharma J, Sardiello M. Lysosome biogenesis in health and disease. J Neurochem. 2019 Mar;148(5):573-589. doi: 10.1111/jnc.14564. Epub 2018 Oct 18. Review.</citation>
    <PMID>30092616</PMID>
  </reference>
  <reference>
    <citation>Lee HJ, Yoon YS, Lee SJ. Mechanism of neuroprotection by trehalose: controversy surrounding autophagy induction. Cell Death Dis. 2018 Jun 15;9(7):712. doi: 10.1038/s41419-018-0749-9. Review.</citation>
    <PMID>29907758</PMID>
  </reference>
  <reference>
    <citation>Palmieri M, Pal R, Nelvagal HR, Lotfi P, Stinnett GR, Seymour ML, Chaudhury A, Bajaj L, Bondar VV, Bremner L, Saleem U, Tse DY, Sanagasetti D, Wu SM, Neilson JR, Pereira FA, Pautler RG, Rodney GG, Cooper JD, Sardiello M. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat Commun. 2017 Feb 6;8:14338. doi: 10.1038/ncomms14338. Erratum in: Nat Commun. 2017 Jun 13;8:15793.</citation>
    <PMID>28165011</PMID>
  </reference>
  <reference>
    <citation>Sardiello M. Transcription factor EB: from master coordinator of lysosomal pathways to candidate therapeutic target in degenerative storage diseases. Ann N Y Acad Sci. 2016 May;1371(1):3-14. doi: 10.1111/nyas.13131. Review.</citation>
    <PMID>27299292</PMID>
  </reference>
  <reference>
    <citation>Schulz A, Ajayi T, Specchio N, de Los Reyes E, Gissen P, Ballon D, Dyke JP, Cahan H, Slasor P, Jacoby D, Kohlsch√ºtter A; CLN2 Study Group. Study of Intraventricular Cerliponase Alfa for CLN2 Disease. N Engl J Med. 2018 May 17;378(20):1898-1907. doi: 10.1056/NEJMoa1712649. Epub 2018 Apr 24.</citation>
    <PMID>29688815</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Fondazione Stella Maris</investigator_affiliation>
    <investigator_full_name>Filippo Maria Santorelli</investigator_full_name>
    <investigator_title>Director Molecular Medicine, Neurogenetics and Neuromuscular Disorders</investigator_title>
  </responsible_party>
  <keyword>Juvenile Neuronal Ceroid-Lipofuscinoses</keyword>
  <keyword>Unified Batten Disease Rating Scale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

